Scinai Immunotherapeutics (SCNI) Receivables - Other (2021 - 2025)

Scinai Immunotherapeutics has disclosed Receivables - Other across 5 years of filings, most recently posting $236000.0 for Q2 2025.

• Receivables - Other for Q2 2025 came in at $236000.0, down 27.16% year-over-year; the trailing twelve-month figure through Jun 2025 was $236000.0 (down 27.16% YoY), and the FY2024 annual result was $213000.0, up 40.13% from the prior year.
• Receivables - Other came in at $236000.0 for Q2 2025 at Scinai Immunotherapeutics, up from $213000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $328000.0 in Q3 2024 to a low of $138000.0 in Q2 2023.
• The 5-year median for Receivables - Other is $232000.0 (2023), against an average of $238800.0.
• Across the five-year window, Receivables - Other plunged 52.45% in 2022 and surged 134.78% in 2024, its largest moves.
• Scinai Immunotherapeutics' Receivables - Other stood at $326000.0 in 2021, then tumbled by 52.45% to $155000.0 in 2022, then dropped by 1.94% to $152000.0 in 2023, then surged by 40.13% to $213000.0 in 2024, then climbed by 10.8% to $236000.0 in 2025.
• The last three Receivables - Other figures came in at $236000.0 (Q2 2025), $213000.0 (Q4 2024), and $328000.0 (Q3 2024), per Business Quant data.